Profiling how female sex steroids affect the brain perimenstrually
- Conditions
- Catamenial epilepsyNeurological - Epilepsy
- Registration Number
- ACTRN12624000803594
- Lead Sponsor
- The University of Auckland
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- Female
- Target Recruitment
- 150
1Participants must be willing and able to give informed consent for participation in the study.
2Female (sex presumed female at birth) aged 18-40 years inclusive
3BMI 18-35
4In the Investigators’ opinion, is able and willing to comply with all study requirements
5Must have been stable either on or off neuroactive medications for around 2 months
1Are older than 40, or under 18 years of age
2Are currently pregnant, lactating or intending to become pregnant
3Current use of any hormonal medication that suppresses the menstrual cycle (hormonal intrauterine implants such as Mirena are acceptable if the person is ovulating)
4Have ever undergone gender affirming surgical or recent hormone treatment procedures
5Have polycystic ovary syndrome or periods so irregular that they more often than not 1 week longer or shorter than their average
6Have premenstrual dysphoric disorder (menstrual cycle related depressive episodes) or menstrual migraine
7Have been regularly using any other medication the research team considers may be a problem for the study measures
8Any planned changes to neuroactive medication in timeframe of study participation
9Inability to speak or read English
10Any other condition judged by the study team as likely to impact on the ability of the participant to complete the study
11In the overseeing clinicians opinion is contraindicated to receive the intervention
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method